Physician profile
Alexander Ramos
NPI 1023497872
$8,735.72
in general payments reported to CMS, 2019-2025
54 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2021: $23.23 · 2022: $1,915 · 2023: $2,346 · 2024: $2,543 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,495 · Education: $62.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,495.18 |
| Education | $62.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,049.82 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $859.15 | 2019-2025 | |
| Neurelis, INC. | $639.90 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $463.01 | 2022-2025 | |
| Lilly USA, LLC | $457.98 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Abbvie INC. | $437.04 | 2022-2025 | |
| Argenx US, INC. | $376.98 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $365.13 | 2022-2025 | |
| Kyowa Kirin, INC. | $320.07 | 2021-2024 | Nourianz |
| Sumitomo Pharma America, INC. | $307.68 | 2023-2024 | Aptiom |
| Eisai INC. | $244.41 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $218.27 | 2022 | |
| Neuropace, INC. | $192.32 | 2022-2025 | |
| Genentech USA, INC. | $156.52 | 2024-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Banner Life Sciences, LLC | $149.71 | 2022-2024 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $148.83 | 2023-2024 | Fycompa |
| Amgen INC. | $138.82 | 2024-2025 | Uplizna |
| Pfizer INC. | $138.42 | 2023-2025 | |
| Inspire Medical Systems, INC. | $137.05 | 2022 | |
| Aquestive Therapeutics, INC. | $123.17 | 2022-2025 | |
| Livanova USA, INC. | $122.70 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $106.36 | 2023-2024 | Vumerity, Spinraza |
| Immedica Pharma US, INC. | $104.93 | 2023-2024 | |
| Harmony Biosciences LLC | $103.15 | 2023-2025 | Wakix |
| Upsher-Smith Laboratories LLC | $94.79 | 2022-2023 | |
| Axsome Therapeutics, INC. | $94.34 | 2023-2024 | Sunosi |
| Avanir Pharmaceuticals, INC. | $89.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $87.48 | 2019-2025 | Strensiq |
| Horizon Therapeutics Plc | $79.33 | 2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $77.86 | 2023-2024 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Pyros Pharmaceuticals, INC. | $74.31 | 2024 | Vigpoder |
| Medtronic USA, INC. | $64.52 | 2019 | |
| Aucta Pharmaceuticals, INC. | $57.81 | 2024-2025 | Motpoly Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $56.77 | 2022 | |
| Acadia Pharmaceuticals INC | $49.85 | 2024 | Daybue |
| Celgene Corporation | $48.30 | 2022-2023 | Zeposia |
| Novo Nordisk INC | $45.34 | 2025 | Wegovy, Ozempic |
| Lundbeck LLC | $38.57 | 2024 | Vyepti |
| Genzyme Corporation | $37.71 | 2019-2025 | |
| Medtronic, INC. | $37.59 | 2024 | Percept PC Brainsense |
| Vanda Pharmaceuticals INC. | $34.84 | 2025 | Ponvory |
| Neurocrine Biosciences, INC. | $32.38 | 2022 | |
| Dexcom, INC. | $28.45 | 2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $25.69 | 2024 | Ajovy |
| Insulet Corporation | $25.34 | 2025 | Omnipod |
| Biocodex, INC. | $24.24 | 2024 | |
| Emd Serono, INC. | $24.20 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.05 | 2022 | |
| Corcept Therapeutics | $24.04 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $24.03 | 2023 | Quviviq |
| Adamas Pharmaceuticals, INC. | $22.83 | 2019 | |
| Antares Pharma, INC. | $20.66 | 2025 | Xyosted |
| Recordati_rare_diseases_inc. | $18.29 | 2025 | Isturisa |
| Biomarin Pharmaceutical INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.